Pathoimmunobiology of
Atopic Dermatitis (AD)


Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Program Medium

Internet-based program

Estimated Time to Complete Educational Activity

1.5 hours

Course Overview

In this web-based program, physicians will learn how recent advances in basic and clinical research have helped to advance the management of atopic dermatitis.

Release Date

January 6, 2017

Expiration Date

January 6, 2019

Method of Physician Participation Utilized in Learning Process

There are no fees for participating and receiving CME credit for this activity. During the period January 6, 2017 through January 6, 2019 participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity, and are expected to view all 5 segments totaling 1.5 hours to successfully complete the activity and earn CME credit; 3) register and complete the evaluation form and post-test; 4) score 100% on the post-test; and 5) print out your CME certificate.


Participation in this WebCAST is complimentary, and clinicians are invited to view this CME-certified program and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support

Supported by an educational grant from Sanofi Genzyme
and Regeneron Pharmaceuticals

Accreditation Statement

This activity has been planned and implemented in accordance with accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Advancing Knowledge in Healthcare, and CMEducation Resources, LLC. University of Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Policy on Faculty & Provider Disclosure

Advancing Knowledge in Healthcare requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to AKH policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Other Credits

American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.
American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

Program Faculty and Disclosure

Lisa A. Beck, MD
Professor, Department of Dermatology
Professor, Department of Medicine, Allergy/ Immunology and Rheumatology
University of Rochester Medical Center School of Medicine and Dentistry
Rochester, NY

Dr Beck has disclosed the following financial relationships: Consultant: AbbVie Inc., Array Biopharma, Celgene Corporation, Genentech, Inc., Ironwood, Janssen Pharmaceuticals, Inc, LEO Pharmaceuticals, Lilly, MedImmune, Novartis, Regeneron Pharmaceuticals, Inc., Unilever and Ziarco
Contracted Research: AbbVie Inc., Genentech, Inc., Regeneron Pharmaceuticals, Inc. Stock: Medtronic, Inc., Pfizer Inc.

Mark Lebwohl, MD
Professor and Chairman
Department of Dermatology
The Mount Sinai School of Medicine
New York, NY

Dr Lebwohl discloses no financial relationships with pharmaceutical or medical product manufacturers.

Emma GuttmanYassky, MD, PhD – Program Chair
Professor and Vice Chair, Dermatology
Director, Center for Excellence in Eczema and Laboratory for Inflammatory Skin Diseases
Icahn School of Medicine at Mount Sinai Medical Center
New York, New York

Consultant: AbbVie Inc., Almirall, Anaco, Asana Biosciences, Celgene Corporation, Dermira Inc., Eli Lilly, Galderma, Glenmark Pharmaceuticals, Kiowa Kirin, LEO Pharmaceuticals, Medimmune, Mitsubishi Tanabe, Novartis, Pfizer Inc., Regeneron, Sanofi-aventis, Stiefel/GlaxoSmithKline, Vitae Contracted Research: Celgene Corporation, Eli Lilly, Glenma, Janssen Biotech, LEO Pharmaceuticals, Medimmune, Novartis, Vitae

AKH Staff/Reviewers

Dorothy Caputo, MA, BSN, RN, Lead Nurse Planner/Reviewer: has disclosed no relevant financial relationships.

Patricia Brignoni, AKH Project Manager/Reviewer: has disclosed no relevant financial relationships.

Kelly Kraines, AKH Senior Director - Projects and Planning, Planner/Reviewer: has disclosed no relevant financial relationships.

Disclosure of Unlabeled Use and Investigational Product

This educational activity will include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclosure Declaration

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Faculty Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other faculty for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review. AKH Inc. and CMEducation Resources, LLC planners and reviewers have no relevant financial relationships to disclose.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.

Educational Objectives

Upon completion of this activity, participants will be able to:

  • Manage patients with moderate-to-severe atopic dermatitis, and understand the lifelong disease burden of AD and associated disorders;
  • Apply national and international professional association-based guidelines for assessment and diagnosis of atopic dermatitis to the front line of patient care;
  • Detail the epidemiology, disease burden, and quality-of-life dimensions associated with atopic dermatitis based on severity of disease and health care disparities;
  • Sequence and combine non-pharmacologic and pharmacologic therapies based on severity of disease, biomarkers, and guidelinedirected roadmaps for optimizing management of atopic dermatitis;
  • Evaluate, monitor, and intervene in patients with moderate-to-severe atopic dermatitis who have treatment failures;
  • List the scientific advances and improvements in our understanding the pathoimmunobiology of atopic dermatitis, with a focus on novel treatment targets, cytokine signaling systems, Th2 immune response, and the role of interleukin-mediated inflammation in AP;
  • Explain the rationale for evaluating biologic agents and targeting new mechanisms-of-action and molecular signatures in patients with moderate-to-severe and/or resistant atopic dermatitis;
  • Apply the results of landmark clinical trials in atopic dermatitis, including those evaluating the safety and efficacy of interleukintargeted therapies, in patients with moderate-tosevere atopic dermatitis.

Hardware and Software Requirements:

To participate in this program, viewers must have a PC or Macintosh computer that has active, ongoing internet access for the duration of the program, as well as a compatible Flash-viewer. An email address is required for registration, and a printer is required to print out the CME certificate.

Privacy Policy

When you participate in a CME activity offered by CMEducation Resources, we ask you for your name, degree, affiliation, street address, telephone number, fax number, and/or e-mail address (the "Information"). We use that Information in the following ways:

  • We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
  • For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
  • We may use the Information to send you information about other CME activities that CMEducation Resources is offering.
  • If our company is acquired by or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
  • You should check this privacy policy periodically to see whether we have made any changes.


Copyright © 2017 by CMEducation Resources, LLC All rights reserved.

Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this webcast reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this webcast is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this webcast is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This webcast is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This webcast is not intended for use by the layman.

Opinions expressed herein are not necessarily those of CMEducation Resources, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations.




I have read this CME information statement and wish to participate in this CME activity.

Copyright © CMEducation Resources, LLC



Key Program Topics Include:

atopic dermatitis
cream in Phase 2

effects on the epidermis in AD


JAK inhibitor
Mycophenolate mofetil
Mycophenolate Mofetil

PDE4 inhibitors
Th2 Cytokine
Vitamin D